FDA Approves Supernus Pharmaceuticals’ Drug Infusion Device ‘Onapgo’ To Treat Parkinson’s Disease

The U.S. Food and Drug Administration (FDA) approved a wearable subcutaneous drug infusion device developed by Supernus Pharmaceuticals to treat motor fluctuations in adults with advanced Parkinson’s disease. The system, called “Onapgo” infuses apomorphine to provide provides continuous treatment during the waking day for more consistent control. The company plans to launch U.S. sales in the second quarter of 2025. At the launch, Supernus will also provide a robust nurse education program, and access support for consumers.

The approval is based on results from a Phase 3, 12-week, multicenter, parallel-group, double-blind, randomized, placebo-controlled . . .